Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria (all must be met):~* Age 6-59 months~* Weight-for-height z-score (WHZ) \< -3 SD or mid-upper arm circumference (MUAC) \< 115 mm~* No nutritional or nutritional edema Grade I and II~* Primary residence within catchment area of enrollment site~* Available for full 8-week study~* Has not been admitted to a nutritional program for the treatment of severe acute malnutrition (SAM) in the 2 preceding weeks~* No antibiotic use in past 7 days~* No clinical complications requiring antibiotic treatment~* No clinical complications requiring inpatient treatment~* No congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip/palate, sickle cell disease, etc)~* No allergy to macrolides/azalides~* Sufficient appetite according to a feeding test with ready-to-use therapeutic food (RUTF)~* Appropriate written informed consent from at least one parent or guardian~Exclusion criteria (any excludes):~* Age \< 6 months or \> 59 months~* WHZ ≥ -3 SD or MUAC ≥ 115 mm~* Primary residence outside catchment area of enrollment site~* Not available for full 8-week study~* Presence of nutritional edema Grade III~* Admission to a nutritional program for the treatment of SAM in the 2 preceding weeks~* Antibiotic use in past 7 days~* Clinical complications requiring antibiotic treatment~* Clinical complications requiring inpatient treatment~* Congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip/palate, etc)~* Allergy to macrolides/azalides~* Insufficient appetite according to a feeding test with ready-to-use therapeutic food (RUTF)~* Parent or guardian refuses to provide consent

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Children in this arm will receive one dose of amoxicillin.
- Amoxicillin (Type: ACTIVE_COMPARATOR): Children in this arm will receive a 5-day course of amoxicillin (standard care).

Based on this trial design, predict the completion outcome and termination type (if applicable).